Working… Menu

Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01798108
Recruitment Status : Completed
First Posted : February 25, 2013
Last Update Posted : May 19, 2017
Information provided by (Responsible Party):

Brief Summary:

A new bone-seeking radiopharmaceutical drug, called Radium-223 dichloride (formerly known as "Alpharadin"), is currently under development. It is an injectable aqueous solution containing radium-223, a radionuclide that emits radiation of another quality and with a different distribution than radiopharmaceuticals currently in use.

After injection of the drug into the blood, a large portion of the drug will accumulate in the bones, and irradiate the skeletal metastases. The drug is expected to be retained longer in the painful sites of bone than in other sites of the body, and may alleviate pain through its radiation. Radium-223 is expected to be both efficacious as regards the targeted localised irradiation, and also to have a favourable safety profile.

The radiopharmaceutical drug Radium-223 has not been given to humans before. In this first clinical study in man, a so-called phase I study, the safety, tolerance and the toxicity of various radioactivity doses of Radium-223 will be evaluated.

Condition or disease Intervention/treatment Phase
Neoplasm Metastasis Radiation: Radium-223 dichloride (BAY88-8223) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Phase I Open-label, Multicenter, Dose-escalating Study of Radium-223 in Patients With Advanced Skeletal Metastases
Actual Study Start Date : August 14, 2001
Actual Primary Completion Date : June 25, 2003
Actual Study Completion Date : June 25, 2003

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Radium-223 dichloride
The study had 2 parts. Part 1a was designed with single injections of Radium-223 given to cohorts of 5 patients for each of 5 pre-defined dose levels. Part 1b was designed to retreat and fractionate the dose of Radium-223 in multiple injections.Based on the revised correction factor by calibration, recalculations verified that the single injection doses administered in the part 1a were : 46, 93, 163, 213 and 250 kBq/kg b.w. Two re-treated patients (dose group 6) received a second dose that resulted in a total dose of 250 kBq/kg b.w. The fractionated doses were 1/5 and ½ of the highest dose in part1b (i.e. 250kBq so 5 x 50 and 2 x 125 kBq/kg b.w. respectively).
Radiation: Radium-223 dichloride (BAY88-8223)
- Single injection. Starting dose 46 kBq/kg b.w. Escalating doses 93, 163, 213 and 250 kBq/kg b.w. (9.8.2 Changes in addition to those described in amendments) After completion of the five dose levels above, the protocol was amended and the study extended to include patients to received multiple injections of Radium-223 - Re-treatment: Patients who had earlier been included in the study and received dose levels 46, 93 or 163 kBq/kg b.w. could be given a second injection, provided that the total dose did not exceed 250 kBq/kg b.w. - Fractionated dose (multiple dosing) Patients were given multiple injections in treatment: 5 injections of 50 kBq/kg b.w. at 3 weeks intervals. Patients were given multiple injections in treatment: 2 injections of 125 kBq/kg b.w. at 6 weeks interval

Primary Outcome Measures :
  1. Number of participants with predetermined adverse events (dose limiting toxicity [DLT]) as a measure of safety and tolerability while dose escalating [ Time Frame: Up to 8 weeks from injection ]

Secondary Outcome Measures :
  1. Blood clearance of radioactivity [ Time Frame: 48 hours after the last injection ]
  2. Quality of Life Questionnaire [ Time Frame: 8 weeks after the last injection ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ≥ 30 years of age
  • has histologically or cytologically confirmed breast or prostate carcinoma
  • presents with bony metastases, confirmed by scintigraphic imaging within the previous 4 weeks
  • relapsing with new foci in the skeleton after previous external radiotherapy
  • has a life expectancy of at least 8 weeks (study part Ia), 5 months for study part Ib
  • good performance status; ECOG (Eastern Cooperative Oncology Group) status 0-2
  • has normal bone marrow, hepatic, renal and cardiac functions
  • clinical chemical laboratory values are within pre-specified range, measured within 7 days prior to dosing day
  • for female patients: post-menopausal, surgically sterile or taking adequate contraceptive precaution

Exclusion Criteria:

  • has previously been included in this study. This criterion is applicable for patients that receive a single injection of the study drug, but not for patients to be re-treated, or for those to receive a fractionated dosing regimen (study part Ib).
  • has received an investigational drug in the 4 weeks before or is scheduled to receiving one during or in the 8 weeks after study drug administration. This criterion is applicable for patients that receive a single injection of the study drug and for patients to be re-treated.
  • has received any other investigational drug than radium-223 in the 4 weeks before first injection of study drug or is scheduled to receiving one during or in the 8 weeks after the fractionated study drug regimen. This criterion is applicable for patients receiving fractionated dose of the study drug.
  • has received chemo-, immuno-, or radiotherapy within the last 4 weeks prior to entry in the study
  • has other active, serious, life-threatening disease with a life expectancy of less than 8 weeks
  • has any uncontrolled infection
  • requires oxygen for pulmonary metastases
  • has poor renal function with S-Creatinine >150 mmol/L (males), >100 mmol/L (females)
  • has heart insufficiency, Class III or IV NYHA (New York Heart Association)
  • is pregnant or lactating
  • for female patients: of childbearing potential, and not taking adequate contraceptive measures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01798108

Layout table for location information
The Norwegian Radium Hospital
Oslo, Norway
University Hospital of North Norway
Tromsoe, Norway
Karolinska University Hospital
Stockholm, Sweden
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Layout table for additonal information
Responsible Party: Bayer Identifier: NCT01798108    
Other Study ID Numbers: 15522
ATI-BC-1 ( Other Identifier: Algeta ASA )
First Posted: February 25, 2013    Key Record Dates
Last Update Posted: May 19, 2017
Last Verified: May 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bayer:
Advanced skeletal metastases
Radium-223 dichloride
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplasms, Second Primary
Neoplastic Processes
Pathologic Processes
Radium Ra 223 dichloride
Antineoplastic Agents